Nuveen Asset Management LLC bought a new position in Xencor Inc (NASDAQ:XNCR) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 270,541 shares of the biopharmaceutical company’s stock, valued at approximately $11,073,000. Nuveen Asset Management LLC owned 0.48% of Xencor as of its most recent filing with the Securities and Exchange Commission.
Other hedge funds have also recently added to or reduced their stakes in the company. Quantamental Technologies LLC acquired a new stake in shares of Xencor in the 2nd quarter worth $76,000. Aperio Group LLC acquired a new stake in shares of Xencor in the 2nd quarter worth $152,000. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in shares of Xencor by 42.2% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,911 shares of the biopharmaceutical company’s stock worth $160,000 after acquiring an additional 1,160 shares during the period. Bank of Montreal Can acquired a new stake in shares of Xencor in the 2nd quarter worth $163,000. Finally, A.R.T. Advisors LLC acquired a new stake in shares of Xencor in the 2nd quarter worth $313,000. Institutional investors own 84.00% of the company’s stock.
Several analysts have recently commented on the stock. BidaskClub cut shares of Xencor from a “buy” rating to a “hold” rating in a research note on Tuesday, August 27th. Mizuho reiterated a “buy” rating and issued a $52.00 price objective on shares of Xencor in a research note on Monday, July 1st. Leerink Swann set a $52.00 price objective on shares of Xencor and gave the company a “buy” rating in a research note on Wednesday, August 7th. Raymond James reiterated a “market perform” rating on shares of Xencor in a research note on Wednesday, August 7th. Finally, Canaccord Genuity raised their price objective on shares of Xencor from $45.00 to $52.00 and gave the company a “buy” rating in a research note on Thursday, August 8th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and nine have issued a buy rating to the company. Xencor presently has an average rating of “Buy” and a consensus target price of $44.62.
Shares of NASDAQ XNCR opened at $34.60 on Friday. The company has a quick ratio of 8.27, a current ratio of 8.27 and a debt-to-equity ratio of 0.02. The firm has a 50-day moving average price of $35.73 and a 200 day moving average price of $36.14. Xencor Inc has a 52 week low of $27.75 and a 52 week high of $46.33. The stock has a market capitalization of $1.95 billion, a price-to-earnings ratio of 42.47 and a beta of 1.37.
Xencor (NASDAQ:XNCR) last posted its earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($0.30) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.45) by $0.15. Xencor had a net margin of 28.46% and a return on equity of 8.40%. The firm had revenue of $19.49 million during the quarter, compared to the consensus estimate of $7.58 million. Equities research analysts expect that Xencor Inc will post 0.05 EPS for the current fiscal year.
Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and other protein therapeutics to treat severe and life threatening diseases with unmet medical needs. It develops its antibody product candidates to treat autoimmune and allergic diseases, cancer, and other conditions.
Featured Article: What does the Dogs of the Dow mean?
Receive News & Ratings for Xencor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor and related companies with MarketBeat.com's FREE daily email newsletter.